Cargando…

A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity

Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP). In contrast to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Thai, Elaine, Costa, Giulia, Weyrich, Anna, Murugan, Rajagopal, Oyen, David, Flores-Garcia, Yevel, Prieto, Katherine, Bosch, Alexandre, Valleriani, Angelo, Wu, Nicholas C., Pholcharee, Tossapol, Scally, Stephen W., Wilson, Ian A., Wardemann, Hedda, Julien, Jean-Philippe, Levashina, Elena A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596816/
https://www.ncbi.nlm.nih.gov/pubmed/32790871
http://dx.doi.org/10.1084/jem.20200061
_version_ 1783602192690708480
author Thai, Elaine
Costa, Giulia
Weyrich, Anna
Murugan, Rajagopal
Oyen, David
Flores-Garcia, Yevel
Prieto, Katherine
Bosch, Alexandre
Valleriani, Angelo
Wu, Nicholas C.
Pholcharee, Tossapol
Scally, Stephen W.
Wilson, Ian A.
Wardemann, Hedda
Julien, Jean-Philippe
Levashina, Elena A.
author_facet Thai, Elaine
Costa, Giulia
Weyrich, Anna
Murugan, Rajagopal
Oyen, David
Flores-Garcia, Yevel
Prieto, Katherine
Bosch, Alexandre
Valleriani, Angelo
Wu, Nicholas C.
Pholcharee, Tossapol
Scally, Stephen W.
Wilson, Ian A.
Wardemann, Hedda
Julien, Jean-Philippe
Levashina, Elena A.
author_sort Thai, Elaine
collection PubMed
description Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP). In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure. Here, we characterized the molecular recognition and functional efficacy of the N-CSP–specific monoclonal antibody 5D5. The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan. Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo. Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines.
format Online
Article
Text
id pubmed-7596816
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-75968162020-11-10 A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity Thai, Elaine Costa, Giulia Weyrich, Anna Murugan, Rajagopal Oyen, David Flores-Garcia, Yevel Prieto, Katherine Bosch, Alexandre Valleriani, Angelo Wu, Nicholas C. Pholcharee, Tossapol Scally, Stephen W. Wilson, Ian A. Wardemann, Hedda Julien, Jean-Philippe Levashina, Elena A. J Exp Med Article Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01. To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP). In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure. Here, we characterized the molecular recognition and functional efficacy of the N-CSP–specific monoclonal antibody 5D5. The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan. Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo. Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines. Rockefeller University Press 2020-08-13 /pmc/articles/PMC7596816/ /pubmed/32790871 http://dx.doi.org/10.1084/jem.20200061 Text en © 2020 Thai et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Thai, Elaine
Costa, Giulia
Weyrich, Anna
Murugan, Rajagopal
Oyen, David
Flores-Garcia, Yevel
Prieto, Katherine
Bosch, Alexandre
Valleriani, Angelo
Wu, Nicholas C.
Pholcharee, Tossapol
Scally, Stephen W.
Wilson, Ian A.
Wardemann, Hedda
Julien, Jean-Philippe
Levashina, Elena A.
A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity
title A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity
title_full A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity
title_fullStr A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity
title_full_unstemmed A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity
title_short A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity
title_sort high-affinity antibody against the csp n-terminal domain lacks plasmodium falciparum inhibitory activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596816/
https://www.ncbi.nlm.nih.gov/pubmed/32790871
http://dx.doi.org/10.1084/jem.20200061
work_keys_str_mv AT thaielaine ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT costagiulia ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT weyrichanna ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT muruganrajagopal ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT oyendavid ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT floresgarciayevel ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT prietokatherine ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT boschalexandre ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT vallerianiangelo ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT wunicholasc ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT pholchareetossapol ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT scallystephenw ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT wilsoniana ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT wardemannhedda ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT julienjeanphilippe ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT levashinaelenaa ahighaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT thaielaine highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT costagiulia highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT weyrichanna highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT muruganrajagopal highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT oyendavid highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT floresgarciayevel highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT prietokatherine highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT boschalexandre highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT vallerianiangelo highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT wunicholasc highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT pholchareetossapol highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT scallystephenw highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT wilsoniana highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT wardemannhedda highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT julienjeanphilippe highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity
AT levashinaelenaa highaffinityantibodyagainstthecspnterminaldomainlacksplasmodiumfalciparuminhibitoryactivity